Selling Androgenic Anabolic Steroids by the Pound: Identification and Analysis of Popular Websites on the Internet

Total Page:16

File Type:pdf, Size:1020Kb

Selling Androgenic Anabolic Steroids by the Pound: Identification and Analysis of Popular Websites on the Internet Scand J Med Sci Sports 2011 & 2011 John Wiley & Sons A/S doi: 10.1111/j.1600-0838.2010.01263.x Selling androgenic anabolic steroids by the pound: identification and analysis of popular websites on the Internet F. G. Cordaro, S. Lombardo, M. Cosentino Department of Clinical Medicine, Section of Experimental and Clinical Pharmacology, University of Insubria, Varese, Italy Corresponding author: Marco Cosentino, MD PhD, Department of Clinical Medicine, Section of Experimental and Clinical Pharmacology, University of Insubria, Via Ottorino Rossi n. 9, 21100 Varese VA, Italy. Tel: 139 0332 217410/397410, Fax: 139 0332 217409/397409, E-mail [email protected] Accepted for publication 18 October 2010 Internet websites offering androgenic anabolic steroids medicines (69.6%) or as dietary supplements (30.4%). (AAS) were identified and available products were exam- AAS in medicines were mainly: nandronole (20.4%), ined. Keywords for the website search were: ‘‘anabolic methandrostenolone (18.4%), and testosterone (12.2%). steroids,’’ ‘‘anabolic steroids buy,’’ ‘‘anabolic steroid pur- Dietary supplements contained mainly DHEA and included chase.’’ The first 10 websites offering AAS in the first 10 several fake compounds. Manufacturers were declared for pages of results were considered. At least two AAS-contain- 97.9% of medicines and 66.7% of dietary supplements; ing products per website were selected. Thirty AAS-selling however, several manufacturers were not found on the websites were identified, mainly located in the United States Internet. Described benefits were usually few adverse effects (46.7%) and Europe (30%). Most websites sold other and no estrogenicity. Toxicity was seldom reported and anabolic/ergogenic products (clenbuterol, 76.7%; GH/ presented as mild. Recommended doses were two–fourfold IGF, 60.0%; thyroid hormones, 46.7%; erythropoietin, higher than current medical recommendations. In conclu- 30.0%; insulin, 20.0%) or products for AAS-related ad- sion, misleading information and deceiving practices were verse effects (mainly: estrogen antagonists, 63.3%; products common findings on AAS-selling websites, indicating their for erectile dysfunction, 56.7%; 5a-reductase inhibitors, deleterious potential for public health. 33.3%; anti-acne products, 33.3%). AAS were sold as Androgenic anabolic steroids (AAS) were identified duced adverse effects target several organs and tis- in the early 1930s; however, the use of extracts from sues, including the cardiovascular system, the liver, rodent or dog testes endowed with ‘‘puissance dyna- the reproductive system, the bones, breast and hair, moge´nique,’’ according to Brown-Se´quard’s defini- skin and vocal cords, and even the central nervous tion, was already popular at the end of 18th century, system. In particular, the central effects of AAS in the context of ‘‘organotherapy’’ (Sneader, 2005). include: increased libido in men and women, which AAS mimic the effects of the male gonadal steroids may be difficult to control, hypomania, heightened testosterone and dihydrotestosterone, resulting in irritability, increased aggression and hostility, de- increased muscle growth and strength. As a conse- structive and self-destructive impulses (Kicman, quence, athletes have been using and abusing AAS 2008). Recently, AAS dependence has been proposed for decades, a fraudulent practice banned since 1975 as a valid diagnostic entity, and probably a growing by the International Olympic Committee and subse- public health problem (Brower, 2009; Kanayama et quently by all major athletic organizations and al., 2009). Indeed, awareness of the risks associated sporting bodies (Verroken & Mottram, 2005). with AAS abuse led several countries to introduce Several therapeutic drugs containing AAS are controls on their use and prescription: in the United available for the treatment of cachexia associated Kingdom, AAS are controlled by the Misuse of with chronic disease as well as for loss of muscle mass Drugs Act (Royal Pharmaceutical Society of Great in the elderly; however, their effects on physical Britain, 2010), in Canada they are included in the function and quality of life are still debated (Kicman, Controlled Drugs and Substances Act (Minister of 2008). On the other side, in sport AAS are well- Justice of Canada, 2010), while the Congress of the known performance enhancers, and their use occurs United States passed the Anabolic Steroid Control at supratherapeutic doses, often taking illicit pre- Act in 1990 (updated in 2004) and AAS were soon parations from the black market, thus leading to an classified as Schedule III substances under the Con- increased risk of serious adverse effects. AAS-in- trolled Substances Act (U.S. Department of Justice, 1 Cordaro et al. 2005). In Italy, as in many other countries, it is illegal (Parkinson & Evans, 2006). Circumstantial evidence to obtain or sell them without a prescription, and indeed suggests that Internet is possibly the primary recently nandrolone has been included in the list of means for buying and selling illicit AAS (Govern- controlled substances in view of its addictive poten- ment Accountability Office, 2005) and a primary tial (Minister of Health of Italy, 2010). source of non-medical AAS information (Perry A major reason for concern is that most AAS users et al., 2005). are not competitive athletes at all, but simply indivi- The present study was therefore devised to identify duals troubled with their ‘‘body image’’ (Buckley et a representative sample of websites offering AAS on al., 1988; Kanayama et al., 2001). Such kind of the Internet and to evaluate their characteristics with ‘‘ordinary’’ AAS users rarely seek treatment and particular regard to the types of products available often distrust and escape physicians, while com- and the kind of information provided. A sample of monly abusing of two or more AAS and often taking products was also selected and the related claims huge doses for prolonged periods (reviewed by Ka- were carefully scrutinized. nayama et al., 2008). The medical and psychiatric consequences of AAS abuse however usually occur after long-term use at supraphysiologic doses, there- Methods fore, because widespread use of AAS began to Internet search emerge only in about 1980, it is likely that the social The search was conducted by one of us (F. G. C.), who acted consequences will become increasingly evident in the as a consumer and attempted to purchase AAS on the next few years, when hundreds of thousands of AAS Internet. The search was performed by use of a personal users begin to pass the age of 45 (Kanayama et al., computer connected to Internet via ADSL, from August 9 to September 29, 2009, using Mozilla Firefox ver. 3.0.15 as 2008). Prevention of AAS misuse is therefore of key Internet browser. Google was selected as the search engine importance and should include, besides random because it accounts for about 65% of Internet searches in the doping analyses, longer disqualifications of AAS- world (Search Engine Watch Staff, 2009) and for up to 88% in using athletes, and tougher legislation against posses- Italy (Bonfils, 2010). The keywords used were ‘‘anabolic sion of AAS, also medical and pedagogic interven- steroids,’’ ‘‘anabolic steroids buy,’’ ‘‘anabolic steroid pur- chase,’’ and the search was performed in English and in tions, particularly targeted to adolescents and other Italian. more vulnerable subjects (Sjo¨qvist et al., 2008; Grey- danus & Patel, 2010). To this end, however, physi- cians and educators must be aware of the attitudes Websites and beliefs of AAS users, which preferentially derive For each combination of keywords, we identified the first 10 from consultation of friends, of people who sold websites that offered AAS (or products presented as such) in them AAS, or even in particular in recent times, the first 10 pages of results. We then recorded for each website specialized Internet sites (Pope et al., 2004). the universal resource locator and the position in the list of Indeed, despite the increasing regulation, available Google results. Additional information about the websites (IP locations and addresses, names of domains, registration/crea- evidence indicates that the world traffic of doping tion/expiration/last update date of domains, registrants/ad- substances and in particular of AAS is sharply ministrators of websites) was subsequently obtained by the use increasing, in particular through the Internet (Do- of WhoIs Source (whois.domaintools.com). Website analysis nati, 2007). Among the various pathways sought by included: website language(s), sold products, drug prescription drug traffic, the Internet is probably the main world- requirements, need for creation of a personal account and subsequent login, indication of a minimum/maximum amount wide channel for easy access to drugs and other of products that could be bought, payment options, and substances. According to a report focused on pain shipment methods. Finally, an image of the website homepage relievers, anxyiolitics, and stimulants, 85% of web- was obtained and the date and hour of the last access to the sites selling controlled drugs did not require buyers website were registered. to have a prescription (The National Center on Addiction and Substance Abuse at Columbia Uni- versity, 2008). Although recently it has been sug- Medicines and other products gested that the Internet is still a relatively minor At least two AAS-containing products were identified for each source for illicit purchases of prescription medica- website. Selection was made
Recommended publications
  • Dehydroepiandrosterone – Is the Fountain of Youth Drying Out?
    Physiol. Res. 52: 397-407, 2003 MINIREVIEW Dehydroepiandrosterone – Is the Fountain of Youth Drying Out? P. CELEC 1,2, L. STÁRKA3 1Faculty of Medicine, 2Faculty of Natural Sciences, Comenius University, Bratislava, Slovakia and 3Institute of Endocrinology, Prague, Czech Republic Received September 15, 2002 Accepted October 7, 2002 Summary Dehydroepiandrosterone (DHEA) and its sulphate-bound form (DHEAS) are important steroids mainly of adrenal origin. Their physiological and pathophysiological functions are not yet fully identified, although a number of various possible features have been hypothesized. Most popular is the description of the “hormone of youth” as the long-term dynamics of DHEA levels are characterized by a sharp age-related decline in the late adulthood and later. Low levels of DHEA are, however, associated not only with the ageing process but also with diabetes mellitus, cardiovascular diseases and some neurological or immunological entities. In the past decade, a number of brief studies have concentrated on these relationships and also on the role of exogenous DHEA in health, disease and human well-being. This article tries to summarize some of the most important facts achieved recently. Key words Dehydroepiandrosterone • Intracrinology • Hormone replacement therapy • Steroids Introduction functions: 1) DHEA is an endogenous metabolite that cannot be patented so that pharmaceutical companies are In 1934 Butenandt and Dannenbaum isolated not interested in supporting research in this field. dehydroepiandrosterone (DHEA) from urine and in 1944 2) DHEA can be described as a “human molecule” Munson and colleagues identified its 3β-sulphate because other investigated species have much lower (DHEAS). Even now, nearly 70 years later, we still do concentrations.
    [Show full text]
  • Download Product Insert (PDF)
    Product Information Boldenone Cypionate Item No. 15158 CAS Registry No.: 106505-90-2 O Formal Name: 17β-hydroxy-androsta-1,4-dien-3-one O cyclopentanepropionate MF: C27H38O3 FW: 410.6 H Purity: ≥95% Stability: ≥2 years at -20°C H H Supplied as: A crystalline solid λ O UV/Vis.: max: 244 nm Laboratory Procedures For long term storage, we suggest that boldenone cypionate be stored as supplied at -20°C. It should be stable for at least two years. Boldenone cypionate is supplied as a crystalline solid. A stock solution may be made by dissolving the boldenone cypionate in the solvent of choice. Boldenone cypionate is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of boldenone cypionate in these solvents is approximately 15, 5, and 25 mg/ml, respectively. Boldenone cypionate is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, boldenone cypionate should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. Boldenone cypionate has a solubility of approximately 0.3 mg/ml in a 1:2 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day. Boldenone is an anabolic androgenic steroid and synthetic derivative of testosterone that was originally developed for veterinary use.1 It can increase nitrogen retention, protein synthesis, and appetite, and also stimulates the release of erythropoietin in the kidneys.1 Boldenone cypionate was synthesized as an ester of boldenone in an attempt to alter boldenone’s very long half-life.2 Anabolic androgenic steroid compounds such as boldenone cypionate have been used illicitly by bodybuilders and other athletes.3 This compound is intended for forensic and research purposes only.
    [Show full text]
  • Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals
    Journal of Clinical Medicine Review Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals Carlotta Cocchetti 1, Jiska Ristori 1, Alessia Romani 1, Mario Maggi 2 and Alessandra Daphne Fisher 1,* 1 Andrology, Women’s Endocrinology and Gender Incongruence Unit, Florence University Hospital, 50139 Florence, Italy; [email protected] (C.C); jiska.ristori@unifi.it (J.R.); [email protected] (A.R.) 2 Department of Experimental, Clinical and Biomedical Sciences, Careggi University Hospital, 50139 Florence, Italy; [email protected]fi.it * Correspondence: fi[email protected] Received: 16 April 2020; Accepted: 18 May 2020; Published: 26 May 2020 Abstract: Introduction: To date no standardized hormonal treatment protocols for non-binary transgender individuals have been described in the literature and there is a lack of data regarding their efficacy and safety. Objectives: To suggest possible treatment strategies for non-binary transgender individuals with non-standardized requests and to emphasize the importance of a personalized clinical approach. Methods: A narrative review of pertinent literature on gender-affirming hormonal treatment in transgender persons was performed using PubMed. Results: New hormonal treatment regimens outside those reported in current guidelines should be considered for non-binary transgender individuals, in order to improve psychological well-being and quality of life. In the present review we suggested the use of hormonal and non-hormonal compounds, which—based on their mechanism of action—could be used in these cases depending on clients’ requests. Conclusion: Requests for an individualized hormonal treatment in non-binary transgender individuals represent a future challenge for professionals managing transgender health care. For each case, clinicians should balance the benefits and risks of a personalized non-standardized treatment, actively involving the person in decisions regarding hormonal treatment.
    [Show full text]
  • Progestogens and Venous Thromboembolism Among Postmenopausal Women Using Hormone Therapy. Marianne Canonico, Geneviève Plu-Bureau, Pierre-Yves Scarabin
    Progestogens and venous thromboembolism among postmenopausal women using hormone therapy. Marianne Canonico, Geneviève Plu-Bureau, Pierre-Yves Scarabin To cite this version: Marianne Canonico, Geneviève Plu-Bureau, Pierre-Yves Scarabin. Progestogens and venous throm- boembolism among postmenopausal women using hormone therapy.. Maturitas, Elsevier, 2011, 70 (4), pp.354-60. 10.1016/j.maturitas.2011.10.002. inserm-01148705 HAL Id: inserm-01148705 https://www.hal.inserm.fr/inserm-01148705 Submitted on 5 May 2015 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Progestogens and VTE Finale version Progestogens and venous thromboembolism among postmenopausal women using hormone therapy Marianne Canonico1,2, Geneviève Plu-Bureau1,3 and Pierre-Yves Scarabin1,2 1 Centre for Research in Epidemiology and Population Health, U1018, Hormones and Cardiovascular Disease 2 University Paris-Sud, UMR-S 1018, Villejuif, France 3 University Paris Descartes and Hôtel-Dieu Hospital, Paris, France Adresse: 16 av. Paul Vaillant Couturier 94807 Villejuif Cedex Tel: +33 1 45 59 51 66 Fax: +33 1 45 59 51 70 Corresponding author: Marianne Canonico ([email protected]) 1/21 Progestogens and VTE Finale version Abstract Hormone therapy (HT) is the most effective treatment for correcting menopausal symptoms after menopause.
    [Show full text]
  • Androgenic-Anabolic Steroid (Boldenone)
    Genera of l P l r a a n c r t u i c o e J Kalmanovich et al., J Gen Pract 2014, 2:3 Journal of General Practice DOI: 10.4172/2329-9126.1000153 ISSN: 2329-9126 Case Report Open Access Androgenic-Anabolic Steroid (Boldenone) Abuse as a Cause of Dilated Cardiomyopathy Eran Kalmanovich*, Sa'ar Minha, Marina Leitman, Zvi Vered and Alex Blatt Assaf Harofeh Medical Center, Aviv University, Israel *Corresponding author: Eran Kalmanovich, Department of Cardiology, Assaf Harofeh Medical Center, Zerifin, Sackler School of Medicine, Tel Aviv University, Israel, Tel: +972-50-5191121; E-mail: [email protected] Received date: Feb 27, 2014, Accepted date: Mar 27, 2014, Published date: Apr 3, 2014 Copyright: © 2014 Kalmanovich E, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Case Presentation At admission 1-year follow up A 34-year old, previously healthy male, presented to the ER with EF% 20% 40% worsening dyspnea over a period of three weeks and the appearance of blood tinged sputum. Soon after presentation, the patient was LA diameter (mm) 3.9 3.8 hypoxemic and required mechanical ventilation. Chest X-ray LA area (cm2) 14.0 20 demonstrated bilateral infiltrates and he was admitted to the ICU with the tentative diagnosis of acute respiratory distress syndrome. LVEDD (cm) 6.1 5.6 Investigation by PICCO, Suggested the presence of heart failure were LVESD (cm) 5.1 3.3 and the patient was transferred to the ICCU.
    [Show full text]
  • Steroid Abuse by School Age Children
    epartment .D of .S Ju U s t ic U.S. Department of Justice e . n o i Drug Enforcement Administration t a r t is D in Office of Diversion Control r m ug d E t A nforcemen www.dea.gov www.DEAdiversion.usdoj.gov epartment .D of .S Ju U s t ic e . n o i t a r t is D in r m ug d E t A nforcemen Office of Diversion Control www.dea.gov STEROID ABUSE BY SCHOOL AGE CHILDREN nce viewed as a problem strictly associated with body builders, Ofitness “buffs,” and professional athletes, abuse of anabolic steroids by school age children has significantly increased over the past decade. The National Institute on Drug Abuse (NIDA) estimates that more than a half million 8th and 10th grade students are now using these dangerous drugs, and increasing numbers of high school seniors do not believe steroids are risky. Students are acquiring and taking anabolic steroids without any knowledge of the dangers associated with steroid abuse. The short- term adverse physical effects of anabolic steroid abuse are fairly well known. However, the long-term adverse physical effects of anabolic steroid abuse have not been studied, and as such, are not known. In addition, this type of abuse may result in harmful side-effects as well as serious injury and death. The abuser in most cases is unaware of these hidden dangers. Presented as a public service by: This guide will help you understand why steroids are being misused, Drug Enforcement Administration and how you can provide counseling and implement procedures to Office of Diversion Control educate our youth about the dangers of these drugs.
    [Show full text]
  • Ameliorative Effects of Lycopene Against Boldenone Undecylenate Toxicity in Albino Rats
    BENHA VETERINARY MEDICAL JOURNAL, VOL. 35, NO. 2: 237-249, DECEMBER , 2018 BENHA UNIVERSITY FACULTY OF VETERINARY MEDICINE Ameliorative Effects of Lycopene against Boldenone Undecylenate Toxicity in Albino Rats Sabra H.M., El-Shawarby R.M., Abosalem M., Nabila M. A., Ibrahim S.S. Department of Forensic Medicine & Toxicology. Faculty of Veterinary. Medicine. Benha University. A B S T R A C T Although anabolic androgenic steroids like boldenone (BOL) may increase lean muscle mass, strength, and the ability to train longer and harder, the serious side effects of steroid are many and may not be reversible. So, the present study was designed to investigate the role of lycopene in improving the oxidative stress of boldenone in male albino rats. Twenty eight male adult rats were equally divided into four groups.1st group (control) that received olive oil once a week (5 mg/kg intramuscularly). 2nd group includes rats received lycopene daily (orally, 60mg/kg body weight). 3rd group includes animals that received intramuscular injections of boldenone once a week (5 mg/Kg body weight). 4th group was co-treated with boldenone and lycopene with the same previous doses of both, the experiment extended for 5 weeks. Intramuscular injection of rats with caused significant increase in total weight gain (TWG), serum total protein and globulin, malandialdehyde (MDA), Lactate dehydrogenase (LDH), creatinine kinase (CK), total protein in skeletal muscle, when compared with the control group. On the other hand, a significant decrease in albumin, Albumin/Globulin (A\G) ratio and superoxide dismutase (SOD) in boldenone group when compared with the control group.
    [Show full text]
  • Role of Androgens, Progestins and Tibolone in the Treatment of Menopausal Symptoms: a Review of the Clinical Evidence
    REVIEW Role of androgens, progestins and tibolone in the treatment of menopausal symptoms: a review of the clinical evidence Maria Garefalakis Abstract: Estrogen-containing hormone therapy (HT) is the most widely prescribed and well- Martha Hickey established treatment for menopausal symptoms. High quality evidence confi rms that estrogen effectively treats hot fl ushes, night sweats and vaginal dryness. Progestins are combined with School of Women’s and Infants’ Health The University of Western Australia, estrogen to prevent endometrial hyperplasia and are sometimes used alone for hot fl ushes, King Edward Memorial Hospital, but are less effective than estrogen for this purpose. Data are confl icting regarding the role of Subiaco, Western Australia, Australia androgens for improving libido and well-being. The synthetic steroid tibolone is widely used in Europe and Australasia and effectively treats hot fl ushes and vaginal dryness. Tibolone may improve libido more effectively than estrogen containing HT in some women. We summarize the data from studies addressing the effi cacy, benefi ts, and risks of androgens, progestins and tibolone in the treatment of menopausal symptoms. Keywords: androgens, testosterone, progestins, tibolone, menopause, therapeutic Introduction Therapeutic estrogens include conjugated equine estrogens, synthetically derived piperazine estrone sulphate, estriol, dienoestrol, micronized estradiol and estradiol valerate. Estradiol may also be given transdermally as a patch or gel, as a slow release percutaneous implant, and more recently as an intranasal spray. Intravaginal estrogens include topical estradiol in the form of a ring or pessary, estriol in pessary or cream form, dienoestrol and conjugated estrogens in the form of creams. In some countries there is increasing prescribing of a combination of estradiol, estrone, and estriol as buccal lozenges or ‘troches’, which are formulated by private compounding pharmacists.
    [Show full text]
  • Dihydrotestosterone (Adractim®) 2.5% Gel for Topical Application
    d g t squeezin l aa StSt gelgel Star gel from this en 0mg0m0mg 2.2.55 5mg5mg 7.7.55 10m1 mg l l 12.12.55 ge g ge ) 15m15mg f 17.17.55 ® 20m20mg g g o 22.22.55 25 25m25mg 1.25 g of g 1.25 1 1.25 1 1 1.25 g of g 1.25 27.5 30mg300mm 32.32.5.5 35m35mg drotestosterone hy 37.5 Put on a pair of gloves Gently squeeze the gel onto the mark on the ruler illustrated below – as instructed on the dispensing label. Leave for five minutes Wipe this laminated information sheet with a damp piece of kitchen paper ready for the next dose. Remove the gloves and wash them in warm soapy water ready for the next dose. of di 40m40mg © GOSH NHS Foundation Trust January 2016 © GOSH NHS Foundation Trust How is it used? Dihydrotestosterone 2.5% gel is for external It should be applied over the use only. required area of skin after washing. The gel should be left to dry for five minutes or so before putting on clothes. 1. 2. 3. Spread over the required area evenly 4. 5. Note: Dihydrotestosterone 2.5% gel should not be applied to any broken areas of skin. 42.42.55 l l 45mg45m45m ge ge 47.47.55 , ® 50mg50mm 52.52.55 55mg55mm 57.57.55 2.5 g of g 2 2.5 2 2.5 g of g 2.5 60mg600m0m 62.62.5.5 Dihydrotestosterone is a synthetic version of a hormone called testosterone.
    [Show full text]
  • Steroids and Other Appearance and Performance Enhancing Drugs (Apeds) Research Report
    Research Report Revised Febrero 2018 Steroids and Other Appearance and Performance Enhancing Drugs (APEDs) Research Report Table of Contents Steroids and Other Appearance and Performance Enhancing Drugs (APEDs) Research Report Introduction What are the different types of APEDs? What is the history of anabolic steroid use? Who uses anabolic steroids? Why are anabolic steroids misused? How are anabolic steroids used? What are the side effects of anabolic steroid misuse? How does anabolic steroid misuse affect behavior? What are the risks of anabolic steroid use in teens? How do anabolic steroids work in the brain? Are anabolic steroids addictive? How are anabolic steroids tested in athletes? What can be done to prevent steroid misuse? What treatments are effective for anabolic steroid misuse? Where can I get further information about steroids? References Page 1 Steroids and Other Appearance and Performance Enhancing Drugs (APEDs) Research Report Esta publicación está disponible para su uso y puede ser reproducida, en su totalidad, sin pedir autorización al NIDA. Se agradece la citación de la fuente, de la siguiente manera: Fuente: Instituto Nacional sobre el Abuso de Drogas; Institutos Nacionales de la Salud; Departamento de Salud y Servicios Humanos de los Estados Unidos. Introduction Appearance and performance enhancing drugs (APEDs) are most often used by males to improve appearance by building muscle mass or to enhance athletic performance. Although they may directly and indirectly have effects on a user’s mood, they do not produce a euphoric high, which makes APEDs distinct from other drugs such as cocaine, heroin, and marijuana. However, users may develop a substance use disorder, defined as continued use despite adverse consequences.
    [Show full text]
  • Spironolactone 2021 Newborn Use Only
    Spironolactone 2021 Newborn use only Alert Spironolactone is a potassium-sparing diuretic and concomitant intake of potassium or ACE inhibitors may lead to hyperkalemia. Indication Diuretic primarily prescribed for its potassium-sparing effect. For heart failure, in conjunction with furosemide. For chronic lung disease, in conjunction with a thiazide diuretic. Bartter syndrome and Gitelman Syndrome. Action Spironolactone is a synthetic steroid that acts as a competitive aldosterone receptor antagonist, so inhibits sodium reabsorption and spares potassium. It is a weak diuretic. It also inhibits the interaction between dihydrotestosterone and the intracellular androgen receptor resulting in moderate antiandrogenic activity. Drug type Non-selective mineralocorticoid receptor antagonist. Trade name Aldactone; Spiractin Presentation Oral suspension prepared in pharmacy: 1 mg/mL; 2.5 mg/mL; 5 mg/mL. Dose 1–3 mg/kg/dose 24 hourly. Dose can be divided into different intervals. Dose adjustment Therapeutic hypothermia – Not applicable. Renal impairment – Refer to precautions section. Hepatic impairment – Refer to precautions section. Maximum dose 3 mg/kg/day Total cumulative dose Route Oral Preparation Oral suspension. Administration Administer undiluted with feeds. Monitoring Serum potassium at regular intervals. Contraindications Hyperkalaemia. Significant renal impairment. Anuria. Adrenal insufficiency. Precautions Use with caution in infants with renal or hepatic impairment. Monitor more frequently if infant is also given potassium. Drug interactions Spironolactone increases the effects of ACE inhibitors (leading to hyperkalemia), digoxin and sotalol. Adverse reactions Hyperkalaemia and metabolic acidosis. Antiandrogenic effects include reduced hirsutism and gynecomastia. There is one case report of an ovarian cyst in a neonate on spironolactone. Spironolactone interferes with 17-hydroxyprogesterone measurement, which is used to screen neonates for congenital adrenal hyperplasia.
    [Show full text]
  • DHEA Sulfate, and Aging: Contribution of the Dheage Study to a Sociobiomedical Issue
    Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: Contribution of the DHEAge Study to a sociobiomedical issue Etienne-Emile Baulieua,b, Guy Thomasc, Sylvie Legraind, Najiba Lahloue, Marc Rogere, Brigitte Debuiref, Veronique Faucounaug, Laurence Girardh, Marie-Pierre Hervyi, Florence Latourj, Marie-Ce´ line Leaudk, Amina Mokranel, He´ le` ne Pitti-Ferrandim, Christophe Trivallef, Olivier de Lacharrie` ren, Stephanie Nouveaun, Brigitte Rakoto-Arisono, Jean-Claude Souberbiellep, Jocelyne Raisonq, Yves Le Boucr, Agathe Raynaudr, Xavier Girerdq, and Franc¸oise Foretteg,j aInstitut National de la Sante´et de la Recherche Me´dicale Unit 488 and Colle`ge de France, 94276 Le Kremlin-Biceˆtre, France; cInstitut National de la Sante´et de la Recherche Me´dicale Unit 444, Hoˆpital Saint-Antoine, 75012 Paris, France; dHoˆpital Bichat, 75877 Paris, France; eHoˆpital Saint-Vincent de Paul, 75014 Paris, France; fHoˆpital Paul Brousse, 94804 Villejuif, France; gFondation Nationale de Ge´rontologie, 75016 Paris, France; hHoˆpital Charles Foix, 94205 Ivry, France; iHoˆpital de Biceˆtre, 94275 Biceˆtre, France; jHoˆpital Broca, 75013 Paris, France; kCentre Jack-Senet, 75015 Paris, France; lHoˆpital Sainte-Perine, 75016 Paris, France; mObservatoire de l’Age, 75017 Paris, France; nL’Ore´al, 92583 Clichy, France; oInstitut de Sexologie, 75116 Paris, France; pHoˆpital Necker, 75015 Paris, France; qHoˆpital Broussais, 75014 Paris, France; and rHoˆpital Trousseau, 75012 Paris, France Contributed by Etienne-Emile Baulieu, December 23, 1999 The secretion and the blood levels of the adrenal steroid dehydro- number of consumers. Extravagant publicity based on fantasy epiandrosterone (DHEA) and its sulfate ester (DHEAS) decrease pro- (‘‘fountain of youth,’’ ‘‘miracle pill’’) or pseudoscientific asser- foundly with age, and the question is posed whether administration tion (‘‘mother hormone,’’ ‘‘antidote for aging’’) has led to of the steroid to compensate for the decline counteracts defects unfounded radical assertions, from superactivity (‘‘keep young,’’ associated with aging.
    [Show full text]